Sandu Pharmaceuticals Ltd
Incorporated in 1985, Sandu Pharmaceuticals
Ltd is a manufacturer of Ayurvedic Medicines.[1]
- Market Cap ₹ 32.8 Cr.
- Current Price ₹ 33.9
- High / Low ₹ 58.8 / 30.6
- Stock P/E 16.0
- Book Value ₹ 43.7
- Dividend Yield 2.36 %
- ROCE 5.47 %
- ROE 3.75 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.77 times its book value
- Company has been maintaining a healthy dividend payout of 34.3%
Cons
- Promoter holding has decreased over last quarter: -5.11%
- The company has delivered a poor sales growth of 6.79% over past five years.
- Promoter holding is low: 37.8%
- Company has a low return on equity of 3.80% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.52 | 38.17 | 38.86 | 42.82 | 49.02 | 49.42 | 48.37 | 58.76 | 65.50 | 65.35 | 67.28 | 67.19 | 67.15 | |
| 32.43 | 35.74 | 35.97 | 40.97 | 46.55 | 47.33 | 46.92 | 56.60 | 62.62 | 62.86 | 64.98 | 64.43 | 64.27 | |
| Operating Profit | 2.09 | 2.43 | 2.89 | 1.85 | 2.47 | 2.09 | 1.45 | 2.16 | 2.88 | 2.49 | 2.30 | 2.76 | 2.88 |
| OPM % | 6.05% | 6.37% | 7.44% | 4.32% | 5.04% | 4.23% | 3.00% | 3.68% | 4.40% | 3.81% | 3.42% | 4.11% | 4.29% |
| 0.33 | 0.14 | 0.12 | 0.56 | 0.12 | 0.57 | 0.45 | 0.19 | 0.08 | 0.33 | 0.42 | 0.17 | 0.15 | |
| Interest | 1.06 | 1.37 | 1.64 | 1.49 | 1.23 | 1.01 | 0.43 | 0.11 | 0.11 | 0.08 | 0.06 | 0.10 | 0.12 |
| Depreciation | 0.54 | 0.57 | 0.69 | 0.87 | 0.60 | 0.64 | 0.55 | 0.56 | 0.53 | 0.52 | 0.58 | 0.67 | 0.67 |
| Profit before tax | 0.82 | 0.63 | 0.68 | 0.05 | 0.76 | 1.01 | 0.92 | 1.68 | 2.32 | 2.22 | 2.08 | 2.16 | 2.24 |
| Tax % | 40.24% | 34.92% | 22.06% | 1,000.00% | 26.32% | 34.65% | 21.74% | 35.12% | 31.47% | 31.08% | 29.33% | 28.24% | |
| 0.50 | 0.41 | 0.54 | -0.44 | 0.56 | 0.67 | 0.72 | 1.09 | 1.59 | 1.52 | 1.46 | 1.55 | 2.05 | |
| EPS in Rs | 0.71 | 0.58 | 0.76 | -0.62 | 0.79 | 0.95 | 1.02 | 1.38 | 1.80 | 1.57 | 1.51 | 1.60 | 2.12 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 36.33% | 41.56% | 0.00% | 52.93% | 49.86% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 7% |
| 3 Years: | 1% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 17% |
| 3 Years: | -1% |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 3% |
| 3 Years: | -15% |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.92 | 8.81 | 9.66 | 9.66 | 9.66 | 9.66 |
| Reserves | 11.13 | 11.06 | 11.60 | 20.33 | 21.00 | 21.71 | 22.16 | 25.57 | 27.66 | 29.58 | 30.93 | 32.36 | 32.57 |
| 9.99 | 12.47 | 11.39 | 10.56 | 9.42 | 6.17 | 1.25 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | |
| 8.67 | 10.91 | 11.33 | 8.46 | 7.03 | 8.67 | 10.92 | 13.45 | 12.81 | 14.92 | 11.83 | 13.71 | 14.14 | |
| Total Liabilities | 36.87 | 41.52 | 41.40 | 46.43 | 44.53 | 43.63 | 41.41 | 46.96 | 49.28 | 54.16 | 52.42 | 55.73 | 56.82 |
| 9.09 | 8.36 | 7.81 | 17.49 | 17.57 | 17.04 | 16.60 | 16.17 | 16.00 | 16.62 | 17.88 | 18.15 | 18.35 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 0.42 | 0.00 | 0.00 | 0.00 |
| Investments | 0.69 | 0.70 | 0.73 | 0.99 | 1.12 | 1.13 | 0.82 | 0.24 | 9.11 | 9.66 | 10.43 | 11.22 | 11.61 |
| 27.09 | 32.46 | 32.86 | 27.95 | 25.84 | 25.46 | 23.99 | 30.55 | 23.69 | 27.46 | 24.11 | 26.36 | 26.86 | |
| Total Assets | 36.87 | 41.52 | 41.40 | 46.43 | 44.53 | 43.63 | 41.41 | 46.96 | 49.28 | 54.16 | 52.42 | 55.73 | 56.82 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.06 | 4.75 | -1.43 | 4.91 | 1.23 | 3.74 | 6.20 | 7.59 | 0.95 | 0.22 | 0.76 | 0.95 | |
| -0.70 | -0.18 | 0.05 | -0.59 | -0.62 | -0.10 | -0.37 | -5.58 | -5.47 | 0.53 | -1.31 | -0.18 | |
| -0.25 | -1.90 | -2.06 | -2.33 | -1.89 | -4.26 | -5.36 | 1.30 | 0.93 | 0.58 | -0.72 | -0.46 | |
| Net Cash Flow | -2.01 | 2.67 | -3.44 | 1.99 | -1.28 | -0.62 | 0.48 | 3.31 | -3.59 | 1.33 | -1.27 | 0.31 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62.38 | 62.73 | 67.16 | 54.13 | 49.81 | 35.45 | 35.32 | 33.23 | 22.23 | 26.75 | 26.42 | 25.86 |
| Inventory Days | 233.52 | 210.09 | 206.51 | 152.04 | 146.77 | 191.00 | 208.65 | 117.86 | 115.06 | 167.70 | 137.28 | 160.90 |
| Days Payable | 76.75 | 103.39 | 100.86 | 58.22 | 38.75 | 60.93 | 83.69 | 70.57 | 69.63 | 98.30 | 46.96 | 51.05 |
| Cash Conversion Cycle | 219.16 | 169.43 | 172.82 | 147.94 | 157.84 | 165.52 | 160.28 | 80.52 | 67.67 | 96.15 | 116.75 | 135.70 |
| Working Capital Days | 101.61 | 68.47 | 104.73 | 60.69 | 30.16 | 40.10 | 72.06 | 39.51 | 42.41 | 52.33 | 56.75 | 62.80 |
| ROCE % | 6.93% | 6.80% | 7.75% | 4.26% | 5.14% | 5.58% | 4.13% | 5.59% | 6.94% | 6.08% | 5.36% | 5.47% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Electricity Purchased Units |
|
|||||||||||
| Fuel Consumed - Diesel Liters |
||||||||||||
| Median Remuneration of Employees INR |
||||||||||||
| Number of Permanent Employees Count |
||||||||||||
| Fuel Consumed - LSHS kg |
||||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Feb - Newspaper publication inrespect of opening of special window for transfer and dematerialisation of shares
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Feb - Newspaper Publication inrespect of Unaudited Financials for the Q ended 31.12.2025
-
Statement Of Deviation And Variation For The Q Ended 31.12.2025
6 Feb - No deviation statement for three preferential raises: Rs2,63,79,653; Rs1,38,05,408; Rs1,31,94,934.
- Unaudited Financials For Quarter And Period Ended 31St December 2025 6 Feb
-
Board Meeting Outcome for Outcome Of The Board Meeting
6 Feb - Board approved unaudited standalone results for quarter/nine months ended 31-Dec-2025; limited review by Dileep & Prithvi.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
SPL is engaged in the business of manufacturing and trading of Ayurveda based medicines under the brand name SANDU